CalciMedica presented preclinical data from studies of Auxora in acute AKI

CalciMedica presented data from preclinical studies of Auxora in acute kidney injury, or AKI, at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference, or AKI & CRRT, in San Diego, CA. David Basile, Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled “The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats.” “At AKI & CRRT, Prof. Basile discussed the most recent preclinical study of Auxora in an acute kidney injury model that used a treatment regimen of three daily doses of drug started six hours after ischemic injury, which resembles the dosing in our clinical protocol. The positive results from this study build on prior preclinical data and indicate that inhibiting Orai1 activity in an AKI model improves kidney function,” said Kenneth Stauderman, Founder and Chief Scientific Officer of CalciMedica. AKI is a serious acute critical illness and denotes a sudden reduction in kidney function, or the organ’s ability to clean and filter the blood, that results from a complication of critical illness. These animal model studies support observations from CalciMedica’s clinical trials, particularly CARDEA, the Company’s Phase 2 trial in patients with severe and critical COVID-19 pneumonia, where AKI was a relatively common co-morbidity or a common sequela of the disease. Compared to placebo-treated patients, Auxora-treated patients in CARDEA had lower levels of key biomarkers associated with kidney injury, lower incidence of treatment-emergent AKI and reduced mortality in those patients with decreased kidney function at the time of treatment.